UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 1-U
Current Report Pursuant to Regulation A
Date of Report: August 13, 2019
(Date of earliest event reported)
Commission File No. 024-10924
CANNABINOID BIOSCIENCES, INC. |
California
(State or other jurisdiction of incorporation or organization)
Cannabinoid Biosciences, Inc.
3699 Wilshire Blvd., Suite 610
Los Angeles, California 90010
(323) 868-6762; (310) 895-1839
franklin@cbdxfund.com
(Address, including zip code, and telephone number,
including area code, of issuer’s principal executive office)
Patience C Ogbozor
3699 Wilshire Blvd., Suite 610
Los Angeles, California 90010
Telephone: (310) 895-1839
cannabinoidbiosciences@gmail.com
(Name, address, including zip code, and telephone number,
including area code, of agent for service)
Copy to:
Azuka L Uzoh, Esq.
Law Office of Azuka L Uzoh
1930 Wilshire Blvd., Suite 1216
Los Angeles, California 90025
Telephone: (213) 483-4020
2834 | 47-1077576 |
(Primary Standard Industrial | (IRS Employer |
Classification Code Number) | Identification Number) |
ITEM 9. | OTHER EVENTS |
Extension of offering period
On August 12, 2018, the Company elected to exercise its right under the Company’s Regulation A+ Offering Circular, dated April 9, 2019, to extend the offering period to July 31, 2020. Accordingly, the Offering will terminate to the first to occur of: (i) the date on which the $50,000,000 Maximum Offering is completed; (ii) July 31, 2020, or (iii) such earlier date as the Company elects to terminate the Offering.
Resignation of Kareem Davis as Chief Development Officer and Company Director
Effective as of August 12, 2019, Kareem Davis as Chief Development Officer and a Director of the Company, resigned from his positions with the Company. There were no disputes between Mr. Davis and the Company with respect to any financial matters or financial disclosures contained in the Company filings with the SEC.
SIGNATURES
Pursuant to the requirements of Regulation A, the issuer has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized in the Los Angeles, State of California, on August 12, 2019.
By: | /s/ Patience C Ogbozor |
Name: Patience C Ogbozor | |
Title: President and Chief Executive Officer | |
